Comparative Pharmacology
Head-to-head clinical analysis: PHENURONE versus PRIMIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENURONE versus PRIMIDONE.
PHENURONE vs PRIMIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
None Documented
None Documented
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Category C
Category D/X
Anticonvulsant
Anticonvulsant